Directory

Full Time Faculty

Victoria Butcko Best Doctors in America logo
William Mieler, MD
Professor
Vice-Chairman
Director, Ocular Oncology

Email wmieler@uic.edu
Phone (312) 996-7832
Office IEEI 2.50
Address University of Illinois at Chicago
Department of Ophthalmology and Visual Sciences
1855 W. Taylor Street M/C 648
Chicago, IL 60612

Specialization

  • Complex macular and retinal diseases
  • Ocular oncology

Research Interests

  • Drug delivery to the posterior segment of the eye (via thermoreversible hydrogels)
  • Ocular pharmacology [Uptake (and potential toxicity) of topical, periocular, and systemic medications]
  • Intraocular tumors and response to therapy
  • Ocular imaging
  • National clinical trials in the treatment of choroidal neovascularization and diabetic macular edema

Clinical Interests
Vitreoretinal surgical diseases, ocular trauma, ocular oncology

Current grants or clinical trials

  • SCORE study. A randomized trial to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema associated with central retinal vein occlusion and branch retinal vein occlusion. Co-investigator, University of Chicago, 2004-present.
  • INSPIRE. Protocol 06-102. A randomized, double-masked, placebo, controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment. Co-investigator, University of Chicago, 2004-05. Principle investigator, 2005-present.
  • Allergan (Posurdex). A six-month, phase 3, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 ug and 350 ug dexamethasone posterior segment drug delivery system (DEX PS DDS applicator system) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion. Co-investigator, University of Chicago, 2004-present.
  • Alcon C-02-60. An evaluation of efficacy and safety of posterior juxtascleral administration of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular  degeneration (AMD). Co-investigator, University of Chicago, 2004-present.
  • Diabetic Retinopathy Clinical Research (DRCR) network. Co-investigator, University of Chicago, 2003-present.
  • The Lincy Foundation Research Grant, A Novel Anti-Angiogenic Drug Delivery System for Treatment of Age-Related Macular Degeneration (AMD) via Thermo-Responsive Hydrogels. Co-principle investigator, U Chicago and IIT, 2006-08.
  • The Macula Foundation, Investigation of Retinal Angiogenesis Inhibition by Methylnaltrexone. Co-principle investigator, U Chicago and IIT, 2007-08.
  • Allergan (DME) AGN206207-011-01, A 3-year, phase 3, multicenter, masked, randomized, sham-controlled trial to  assess the safety and efficacy of 700 ug and 350 ug Dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with diabetic macular edema. Co-investigator, U Chicago, 2006-present
  • Alimara (FAME) A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 micrograms/day and ASI-001B 0.2 micrograms/day Fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema. Co-investigator, 2005-present.
  • Eyetech (LEVEL Study)  A phase IV, open label, multi-center, trial of maintenance intravitreal injection of Macugen (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement. Principle investigator, U Chicago, 2007-present.
  • Genentech (DME) An open-label, phase I/II, prospective, triple-arm, randomized, unmasked, pilot study of the activity, efficacy and tolerability of ranibizumab 0.5 mg intravitreal injection for the treatment of diabetic macular edema (DME) in subjects following elective cataract surgery. Principle investigator, U Chicago 2006-present.
  • Genentech (NVG)  An open-label, phase I/II, randomized, prospective, double-arm unmasked pilot study of the activity, efficacy and tolerability of ranibizumab 0.3 mg intravitreal injection as compared to ranibizumab 0.5 mg intravitreal injection for the treatment of neovascularization of the iris and neovascular glaucoma. Co-investigator, U Chicago, 2006-present.
  • Genentech (DME, FVF 4168g/4170g)  A phase III, double-masked, multi-center, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus. Co-investigator, U Chicago, 2007-present.
  • Novartis (DENALI) A 24 month, randomized, double-masked, controlled, multi-center, phase IIIB study assessing safety and efficacy of verteportin (Visudyne) photodynamic therapy administration in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis monotherapy) in patients with subfoveal choroidal neovascularization seconaary to age-realted macular degeneration. Principle investigator, 2007-present.
  • NeoVista (CABERNET), Principle Investigator, U Chicago, 2007-08
  • Occulogix (RHEO-AMD-01)  Safety and effectiveness in a multi-center, randomized, sham-controlled, investigation for age-related macular degeneration (AMD) using rheopheresis treatment. Principle investigator, U Chicago, 2007-08

Education

1975 B.S.: Chemistry University of Wisconsin‑Madison (Phi Kappa Phi)
1979 M.D.: University of Wisconsin‑Madison, Medical School (Alpha Omega Alpha)
1979‑1980 Internship: Flexible, Mercy Hospital and Medical Center,  San Diego, CA
1980‑1983 Residency: Ophthalmology, Bascom Palmer Eye Institute,  University of Miami, Miami, FL
1983 - 1984 Fellowship: Retina‑Vitreous, The Eye Institute, Milwaukee County Medical Complex, Medical College of Wisconsin, Milwaukee, WI
1984 - 1985 Chief Resident: Ophthalmology, Bascom Palmer Eye Institute
Clinical Instructor: University of Miami, Miami, FL
1985 - 1986 Fellowship: Ocular Oncology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA

UIC Appointments
08/08-present: Professor and Vice-Chairman, Department of Ophthalmology & Visual Science, University of Illinois at Chicago (UIC)

Previous Appointments (Academic)
07/84-06/85 Clinical Instructor ‑ Chief Resident, Bascom Palmer Eye  Institute, University of Miami, Miami, FL
07/85-06/89 Assistant Professor of Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI
07/85‑07/99 Co-Director Ocular Oncology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI
07/89‑06/93 Associate Professor of Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI
01/86‑07/99 Staff Physician, Veterans Administration Hospital, Milwaukee, WI
06/89‑07/99 Staff Physician, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI
07/92-07/99 Chief, Vitreoretinal Service, The Eye Institute
12/92-07/99 Courtesy Staff, St. Joseph's Hospital, Milwaukee, WI
07/93-07/99 Professor of Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI
01/98-07/99 The Jack A. and Elaine D. Klieger Chair in Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI
07/99-04/04 Professor of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX
07/99-04/04 Staff Physician, Veterans Administration Hospital, Houston, TX
08/99-04/04 Staff Physician, MD Anderson Cancer Hospital, University of Houston, Houston, TX
08/99-04/04 Staff Physician, St. Luke’s Hospital, Houston, TX
04/04-06/08 Professor and Chairman, Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL
11/07-06/08 Residency Program Director, University of Chicago

Recent Awards

Dr. William Mieler, professor of ophthalmology, received a 2011 Life Achievement Honor Award from the American Academy of Ophthalmology. Dr. Mieler also received the Founders Award and presented the Founders Award Lecture at the American Society of Retina Specialists (ASRS) annual meeting.

Recent publications

  • Hariprasad SM, Miller L, Mieler WF, Grassi M, Green JL, Jager RD: Vision-related quality of life in patients with diabetic macular edema. Br J Ophthlamol 92:89-92, 2008.
  • Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group: Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 126:1152-1156, 2008.
  • Kang Derwent, JJ, Mieler WF: Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc 106:206-214, 2008.
  • Kiernan DF, Hariprasad SM, Chin E, Rago J, Mieler WF: Prospective comparison of fourier domain Cirrus optical coherence tomography versus time domain Stratus OCT for quantifying retinal thickness. Am J Ophthalmol 147:267-275, 2009.
  • Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF: Treatment of cystoid macular edema with the new-generation NSAID Nepafenac 0.1%. Clin Ophthalmol 3:147-154, 2009.
  • Gabrielan A, Hariprasad SM, Jager JD, Green JL, Mieler WF: The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life. Eye (2009-in press).
  • Kiernan DF, Hariprasad SM, Mieler WF: Modern high resolution OCT systems. Ophthalmology International (2009-in press)
  • Mojica G, Hariprasad SM, Jager RD, Mieler WF:  Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 92:584, 2008.
  • Jager RD, Mieler WF, Miller JW:  Age-Related Macular Degeneration (review). N Engl J Med 358:2606-2617, 2008.
  • Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Voriconazole in the treatment of fungal eye infections:  a review of the current literature. Br J Ophthalmol 92:871-878, 2008.
  • Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R;  Toxoplasmosis Study Group:   Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 126:1152-1156, 2008.
  • Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN:  Aqueous and vitreous concentration following topical administration of 1% voriconazole in humans. Arch Ophthalmol 126:18-22, 2008.
  • Hariprasad SM, Miller L, Mieler WF, Grassi M, Green JL, Jager RD:  Vision-related quality of life in patients with diabetic macular edema. Br J Ophthlamol 92:89-92, 2008.
  • Samuel MA, Equi RA, Chang TS, Mieler WF, Jampol L, Hay D, Yannuzzi LA:  Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVA): new observations and a proposed staging system. Ophthalmol 114:1526-1529, 2007.
  • Coffee RE, Westfall AC, Davis GH, Mieler WF, Holz ER: Symptomatic posterior vitreous detachment and the incidence of delayed retinal breaks:  case series and meta-analysis. Am J Ophthalmol 144:409-413, 2007.
  • Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS:  Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 143:365-367, 2007.
  • Regillo CD, D’Amico DJ, Mieler WF, Schneebaum C, Beasley CH, Sulins GT:  Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration. Surv Ophthalmol 52(S):70-78, 2007.

Cirriculum Vitae
View Dr. Mieler's CV.